TORONTO, Aug. 1, 2024 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, announced today that it will release financial results for the quarter ended June 30, 2024, after market close on Thursday, August 8th, 2024. The Company will also host a conference call that day at 5:00 p.m. eastern time to discuss the second quarter 2024 results in further detail.
To access the conference call, please dial (800) 717-1738 (U.S.) or (646) 307-1865 (International) ten minutes prior to the start time and reference Conference ID number 04296. The call will also be available via live webcast on the investor relations portion of the Company's website located at investor.newtopia.com.
If you cannot listen to the conference call at its scheduled time, there will be a replay available through August 29, 2024, which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 11156555. The webcast will also be archived on the Company's website.
About Newtopia
Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social, and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com, LinkedIn or X.
Last Trade: | C$0.005 |
Daily Volume: | 0 |
Market Cap: | C$866K |
November 27, 2024 September 24, 2024 September 17, 2024 August 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load